SciELO - Scientific Electronic Library Online

 
vol.59 issue3Evaluation of exhaled nitric oxide in patients undergoing myocardial revascularization with cardiopulmonary bypassThe importance of intraoperative hyperchloremia author indexsubject indexarticles search
Home Pagealphabetic serial listing  

Services on Demand

Article

Indicators

Related links

Share


Revista Brasileira de Anestesiologia

Print version ISSN 0034-7094

Rev. Bras. Anestesiol. vol.59 no.3 Campinas May/June 2009

http://dx.doi.org/10.1590/S0034-70942009000300004 

SCIENTIFIC ARTICLE

 

Proinflammatory cytokines in patients with neuropathic pain treated with Tramadol*

 

Interleucinas proinflamatorias en pacientes con color neuropático sometidos a tratamiento con Tramadol

 

 

Durval Campos Kraychete, TSA, M.D.I; Rioko Kimiko Sakata, TSA, M.D.II; Adriana Machado Issy, M.D.III; Olívia Bacellar, M.D.IV; Rogério Santos Jesus, M.D.V; Edgar M Carvalho, M.D.VI

IProfessor Adjunto de Anestesiologia da UFBA
IIProfessora Associada da UNIFESP
IIIProfessora Adjunta da Disciplina de Anestesiologia, Dor e Terapia Intensiva da UNIFESP
IVBioquímica do Laboratório de Imunologia da UFBA
V Psiquiatra e Estatístico da UFBA
VIProfessor Titular da UFBA

Correspondence to

 

 


SUMMARY

BACKGROUND AND METHODS: Proinflammatory cytokines play an important role in the pathophysiology of neuropathic pain syndromes. The objective of this study was to evaluate plasma levels of proinflammatory cytokines before and after treatment with tramadol in patients with herniated intervertebral disks and carpal tunnel syndrome, and to compare them with normal individuals.
METHODS: Thirty-eight patients with neuropathic pain secondary to herniated intervertebral disks or carpal tunnel syndrome participated in this study. All patients were treated with controlled release tramadol (100 mg every 12 hours) for 10 days. Venous blood (5 mL) was collected in the morning, before treatment and on the 11th day, and stored (-70° C) until analysis. ELISA was used to determine the plasma levels of cytokines (TNF-
α, IL-1, IL-6) and receptors sTNF-R1 (R & D Systems). Plasma levels of cytokines of 10 healthy volunteers were also determined.
RESULTS: The concentration of TNF-
α before (5.8 ± 2.8 pg.mL-1) was significantly higher than after treatment with tramadol (4.8 ± 2.1 pg.mL-1; p = 0.04, Mann-Whitney test). The levels of IL-1β, IL-6, and sTNF-R1 before and after treatment with tramadol showed no significant differences. Plasma levels of TNF-α (healthy individuals: 1.4 ± 0.5; pain patients: 5.8 ± 2.8 pg.mL-1; p = 0.01) and IL-6 (healthy individuals: 1.2 ± 0.8; pain patients: 3.5 ± 2.6 pg.mL-1; p = 0.01) were significantly higher in patients with neuropathic pain, Mann-Whitney Test.
CONCLUSIONS: In patients with herniated intervertebral disks and carpal tunnel syndrome, plasma levels of TNF-
α and IL-6 were higher than in healthy volunteers, while differences in the concentrations of sTNF-R and IL-1β were not observed. Plasma levels of TNF-α, but not of IL-6, sTNF-R, and IL-1β, decreased after treatment with tramadol (100 mg every 12 hours).

Keywords: ANALGESIC: tramadol; CYTOKINES: IL-1, IL-6, TNF-α, sTNF-R; PAIN, neuropathic: herniated intervertebral disk, carpal tunnel syndrome.


RESUMEN

JUSTIFICATIVA Y OBJETIVOS: Las interleucinas proinflamatorias tienen una función importante en la fisiopatología de los síndromes dolorosos neuropáticos. El objetivo de este estudio, fue evaluar los niveles plasmáticos de interleucinas proinflamatorias antes y después del tratamiento con tramadol en pacientes con hernia de disco y síndrome del túnel del carpo, y compararlos con individuos normales.
MÉTODO: Se investigaron 38 pacientes con dolor neuropático por hernia de disco o síndrome del túnel del carpo. Todos los pacientes fueron tratados con tramadol de liberación controlada (100 mg en 12h) durante 10 días. Se realizaron muestras de sangre venosa (5 mL), por la mañana, antes del tratamiento y en el 11º día, y las mismas se almacenaron para ser analizadas (-70ºC). Se utilizaron test enzimáticos ELISA para la dosificación de las interleucinas plasmáticas (TNF-
α, IL-1, IL-6) y receptores sTNF-R1, (R & D Systems). Se realizó la dosificación de interleucinas en suero de 10 voluntarios sanos.
RESULTADOS: La concentración de TNF-
α antes (5,8 ± 2,8 pg.mL-1) fue significativamente mayor que después del tramadol (4,8 ± 2,1 pg.mL-1; p = 0,04, Test de Mann-Whitney). No hubo diferencia significativa de IL-1β, IL-6 y sTNF-R1 antes y después del tratamiento. Las concentraciones plasmáticas de TNF-α (sanos: 1,4 ± 0,5; pacientes con dolor: 5,8 ± 2,8 pg.mL-1; p = 0.01) y IL-6 (sanos: 1,2 ± 0,8; pacientes con dolor: 3.5 ± 2,6 pg.mL-1; p = 0,01) fueron significativamente mayores en los pacientes con dolor neuropático que en los voluntarios, test de Mann-Whitney.
CONCLUSIONES: En los pacientes con hernia discal y síndrome del túnel del carpo, las concentraciones plasmáticas de TNF-
α y IL-6, fueron más elevadas que en los voluntarios sanos, no habiendo ninguna diferencia en las concentraciones de sTNF-R y IL-1β. Hubo una reducción de la concentración plasmática de TNF-α; después del tratamiento con tramadol (100 mg en 12h), pero no de IL-6 sTNF-R y IL-1β.


 

 

INTRODUCTION

Recent studies that have established the relationship between neuroimmune function and nociception are focused on understanding the role of cytokines, chemokines, and neurotrophins on the development and maintenance of chronic pain syndromes, especially neuropathic pain 1-3.

Experimental models in vertebrates and invertebrates also suggest the presence of modulation of synaptic activity by cytokines (IL-1β, TNF-α, IL-6, and IL-8) when they are administered by different routes (peritoneal 4, plantar 5, subcutaneous 6, neural 7, and epineural 8), increasing the efficacy of nerve transmission, similarly to what is seen in neuropathic pain syndromes, i.e., a reduction in the nociceptive response threshold and generation of ectopic neuronal activity in sensitive afferents Aδ and C fibers 9.

TNF-α is considered the prototype proinflammatory cytokine due to its ability of direct activation of signal transducers, receptors, and channels in nociceptive afferent fibers and other cytokines 10, neurotrophic factors 11, bradykinin 12, and the neurovegetative system 13, and of changing synaptic plasticity into a state of long-term facilitation 5. Tumor necrosis factor-α can be released by different cells, including Schwann cells, and exert its actions by interacting with type 1 TNF-α receptor (sTNF-R1), whose expression is increased after neuronal damage 4.

Several studies have emphasized the prevalence of elevated levels of proinflammatory cytokines in the CSF, plasma, or at the site of tissue damage in patients with chronic pain 1-3,15. Those authors tried to correlate plasma levels of cytokines with pain intensity or symptom severity; however, those studies had a small population, which hinders analysis of the data. The importance of associating elevated serum levels of kinins with chronic pain would indicate a new therapeutic approach, stimulating clinical and experimental studies with antagonists of those substances.

The objective of this study was to evaluate the prevalence of elevated plasma levels of proinflammatory cytokines (IL-1β, TNF-α, IL-6) and receptors sTNF-R1 in patients with chronic muscle-skeletal and neuropathic pain and compare them with normal individuals, as well as to observe the level of those substances after treatment with tramadol hydrochloride.

 

METHODS

After approval by the Ethics Committee and signing of the informed consent, an exploratory, transversal study was conducted with 38 patients, ages 18 to 65 years, who had pain greater than four in the verbal numeric scale for more than three months.

Patients were admitted in the study sequentially; history and standardized general physical, orthopedic, and neurological exams aiming at pain evaluation were conducted. Patients with herniated lumbar or cervical disks, confirmed by MRI, or with carpal tunnel syndrome confirmed by electroneuromyography were included in the study. Patients with psychiatric, systemic inflammatory, viral, parasitic, bacterial, or hepatic diseases, as well as those with a history of allergies and cancer, were excluded from the study.

Pain was evaluated by a numeric scale (0 to 10) where zero represents absence of pain and ten is the worst possible pain.

Sample size was based on literature reports and on a preliminary study with 10 patients, ages between 18 and 65 years, with herniated lumbar disk (n = 7) or carpal tunnel syndrome (n = 3), with severe pain, in which TNF-α levels were 1.68 to 10.7 times greater than the standard level, which was 1.25 pg.mL-1.

Patients were selected among those treated at the outpatient clinic.

They were treated with 100 mg of slow release tramadol hydrochloride every 12 hours for 10 days.

Before institution of the treatment and on the 11th day, 5 mL of venous blood were collected in a simple tube, without anticoagulant, centrifuged to remove the plasma, and stored at -70°C until they were analyzed. ELISA tests were used to determine the plasma levels of cytokines (TNF-α, IL-1, and IL-6) and their receptors, sTNFR1 (R & D Systems).

Exams were conducted at the Immunology Department of the Hospital Universitário Professor Edgard Santos (Salvador, Bahia, Brazil).

Plasma cytokines levels of 10 healthy individuals, ages 18 to 65 years, were also measured for comparison.

The Mann-Whitney test (abnormal distribution curve) was used to compare cytokine levels among patients and the control group and to evaluate the intragroup difference in mean cytokines levels of dichotomic categorical variables. The Wilcoxon test was used for paired analysis. Spearman's coefficient was used to determine the correlation among cytokines and clinical parameters related to continuous variables. The software SPSS version 9.0 was used, and on statistical analysis the probability of a type I error < 5% (p < 0.05) was considered significant.

 

RESULTS

Out of 38 patients, 26 (76.3%) had herniated lumbar (n = 26) or cervical (n = 3) disks, and nine (23.7%) had carpal tunnel syndrome. Due to the size of the study sample, patients were analyzed as a single group. Patients had a mean age of 42 ± 9 years; mean weight 66 ± 11 kg; height of 163 ± 9 cm; and body mass index of 25 ± 4 kg.m-2. As for gender, 36.8% were males and 63.2% females.

Changes in physical exam included: hypoesthesia (22 patients), decreased muscle strength (9 patients), changes in tendon reflexes (6 patients), and muscular atrophy (1 patient). Twenty-seven patients finished the study.

Pain severity was of 9 ± 2 by the numeric scale and it had a duration of 88 ± 114 months.

Plasma levels of TNF-α and IL-6 were significantly higher in patients than in the control group (Table I). The levels of TNF-α decreased significantly after treatment with tramadol. Pre- and post-treatment levels of IL-1β, IL-6, and sTNF-R1 were not statistically significant (Table II).

 

 

 

 

According to Spearman's coefficient, pain severity and cytokine levels were not related (Table III).

 

 

DISCUSSION

In the present study, elevated plasma levels of IL-6 and TNF-α in patients with herniated intervertebral disks (lumbar or cervical) and carpal tunnel syndrome with moderate or severe pain were observed. Authors have correlated the increased plasma levels of cytokines, pain, and disease severity with osteoarticular pain 16 and complex regional pain syndrome 17. One study demonstrated some association between increased levels of IL-6, low levels of cortisol, and symptom severity in patients with herniated intervertebral disks 16. In another study, peak plasma levels of IL-6 were higher at night in the group of patients with sciatic pain and cortisol levels did not increase upon awakening, favoring the idea of a circadian level for cytokines release and possible dysfunction of the hypothalamic-hypophyseal axis for cortisol production 17. An experimental study in animals showed that the peripheral administration of cytokines induces the expression of messenger RNA (c-fos) in hypothalamic nuclei responsible for the synthesis of corticotrophin-releasing hormone, and in central noradrenergic fibers that regulate the secretion of corticotrophin-releasing hormone 18. Thus, cytokines could activate the neuro-endocrine axis, increasing the secretion of cortisol. This would modulate the hyperalgic response of cytokines, reducing pain, and would work as a negative-feedback system. Failure of this system could explain the prolonged release and increase in the secretion of those substances in the plasma. Another possibility would be an altered immune response, with a reduction in the production of IL-10 and IL-4, as has been demonstrated in the CSF or plasma of patients with chronic pain 19,20. Those substances modulate the excessive or prolonged release of pro-inflammatory cytokines 21, and some authors demonstrated a reduction of hyperalgia after immunotherapy with IL-10 22.

The interaction between the local production and plasma levels of cytokines in tissue trauma has not been explained. According to one of the hypothesis, there is a bidirectional communication between the peripheral and central nervous system on the perception of aggression, i.e., activation of a nociceptive fiber and the secretion of cytokines at the site of injury would cause those substances to be released into the blood stream, as well as other hypothalamic-hypophyseal hormones, especially in acute inflammation 23. It is intriguing that, in the acute phase, the objective of hyperalgia is to maintain the patient immobilized in bed for a speedy recovery of organic homeostasis; however, in chronic pain, this would be physiologically illogical. To justify the relationship between the systemic increase in cytokines and localized pain, one should infer that circulating cytokines would only amplify the signal of the damaged nociceptive fiber, probably through the identification of surface markers on the nerve membrane. In the present study, a correlation between pain severity and duration and plasma levels of cytokines was not observed. Fixed pain scores (mode of 10) and the size of the study population could probably be confounding factors in the statistical analysis.

Plasma levels of IL-1β and sTNF-R1 within normal limits, different than the results reported by other authors 1,20 for neuropathic pain, could be explained by differences in the release sequence of those substances, internalization of the specific cytokine-receptor complex, modulation of cytokines secretion by other neuromediators, lack of proportion between the amount of cytokines and receptors, differences in genetic constitution, or failure in transduction signal mechanisms 24.

Treatment of osteomuscular and neuropathic pain involves the use of opioids, anticonvulsants, and antidepressants 25,26. Tramadol exerts its actions in opioid and monoaminergic receptors, with therapeutic possibilities and advantages related with its low toxicity and addictive potential, and its side effects are well-tolerated 27. Since this was an exploratory, transversal study and not a clinical assay, assumptions on the role of tramadol on the immune system and pain transmission cannot be made; however, the results obtained with tramadol favor the idea that it can be used in future clinical studies. Since this study did not have a placebo-controlled group, it is possible that pain relief was not promoted only by the use of tramadol; some of this effect could be due to the natural evolution of the disease.

It can be concluded that in patients with herniated intervertebral disks and carpal tunnel syndrome, plasma levels of TNF-α and IL-6 were higher than in normal individuals, while those of sTNF-R and IL-1β showed no differences. Plasma levels of TNF-α decreased after treatment with tramadol (100 mg every 12 hours), but not those of IL-6, sTNF-R, and IL-1β.

Further studies are necessary to evaluate the relationship between plasma levels of proinflammatory cytokines and pain severity, activities of daily life, psychological profile, physical incapacity, prognosis, and response to treatment. This could validate cytokines as possible markers in the evaluation and measurement of chronic pain. Two causes of chronic pain were studied; therefore, there can be differences in the plasma levels of cytokines. Treatment of chronic pain is difficult and often frustrating. The discovery of new inhibitors or modulators of the production of cytokines represents a new possibility of clinical treatment, since current treatment options are limited.

 

REFERENCES

01. Backonja MM, Coe CL, Muller DA et al. - Altered cytokine levels in the blood and cerebrospinal fluid of chronic pain patients. J Neuroimmunol 2008;195:157-163.         [ Links ]

02. Alexander GM, van Rijn MA, van Hilten JJ et al. - Changes in cerebrospinal fluid levels of pro-inflammatory cytokines in CRPS. Pain 2005;116:213-219        [ Links ]

03. Van de Beek WJ, Remarque EJ, Westendorp RGJ et al. - Innate cytokine profile in patients with complex regional pain syndrome is normal. Pain 2001;91:259-261.         [ Links ]

04. Watkins LR, Wiertelak EP, Goehler LE et al. - Characterization of cytokine-induced hyperalgesia. Brain Res 1994;654:15- 26.         [ Links ]

05. Woolf CJ, Allchorne A, Safieh-Garabedian B et al. - Cytokines, nerve growth factor and inflammatory hyperalgesia: the contribution of tumour necrosis factor alpha. Br J Pharmacol 1997;121:417-424.         [ Links ]

06. Junger H, Sorkin LS - Nociceptive and inflammatory effects of subcutaneous TNFalpha. Pain 2000;85:145-151.         [ Links ]

07. Wagner R, Myers RR - Endoneurial injection of TNF-alpha produces neuropathic pain behaviors. Neuroreport 1996;7: 2897-2901.         [ Links ]

08. Sorkin LS, Xiao WH, Wagner R et al. - Tumour necrosis factor-alpha induces ectopic activity in nociceptive primary afferent fibres. Neuroscience 1997;81:255-262.         [ Links ]

09. Clatworthy AL, Castro GA, Budelmann BU et al. - Induction of a cellular defense reaction is accompanied by an increase in sensory neuron excitability in aplysia. J Neurosci 1994;14:3263-3270.         [ Links ]

10. Sommer C, Kress M - Recent findings on how proinflammatory cytokines cause pain: peripheral mechanisms in inflammatory and neuropathic hyperalgesia. Neurosci Lett 2004;361:184-187.         [ Links ]

11. McDermott MF - TNF and TNFR biology in health and disease. Cell Mol Biol 2001;47:619-635.         [ Links ]

12. Ferreira SH, Lorenzetti BB, Cunha FQ et al. - Bradykinin release of TNF-alpha plays a key role in the development of inflammatory hyperalgesia. Agents Actions 1993;38:C7-9.         [ Links ]

13. Cunha FQ, Lorenzetti BB, Poole S et al. - Interleukin-8 as a mediator of sympathetic pain. Br J Pharmacol 1991;104:765-767.         [ Links ]

14. Schafers M, Geis C, Svensson CI et al. - Selective increase of tumour necrosis factor-alpha in injured and spared myelinated primary afferents after chronic constrictive injury of rat sciatic nerve. Eur J Neurosci 2003;17:791-804.         [ Links ]

15. Brisby H, Olmarker K, Larsson K et al. - Proinflammatory cytokines in cerebrospinal fluid and serum in patients with disc herniation and sciatica. Eur Spine J 2002;11:62-66.         [ Links ]

16. Geiss A, Varadi E, Steinbach K et al. - Psychoneuroimmunological correlates of persisting sciatic pain in patients who underwent discectomy. Neurosci Lett 1997;237:65-68.         [ Links ]

17. Kunz-Ebrecht SR, Mohamed-Ali V, Feldman PJ et al. - Cortisol responses to mild psychological stress are inversely associated with proinflammatory cytokines. Brain Behav Immun 2003;17:373-383.         [ Links ]

18. Machelska H, Stein C - Immune mechanisms in pain control. Anesth Analg 2002;95:1002-1008.         [ Links ]

19. Uceyler N, Valenza R, Stock M et al. - Reduced levels of antiinflammatory cytokines in patients with chronic widespread pain. Arthritis Rheum 2006;54:2656-2664.         [ Links ]

20. Uceyler N, Rogausch JP, Toyka KV et al. - Differential expression of cytokines in painful and painless neuropathies. Neurology 2007;69:42-49.         [ Links ]

21. Mosmann TR, Coffman RL - TH1 and TH2 cells: Different patterns of lymphokine secretion lead to different functional properties. Annu Rev Immunol 1989;7:145-173.         [ Links ]

22. Plunkett JA, Yu CG, Easton JM et al. - Effects of interleukin-10 (IL-10) on pain behavior and gene expression following excitotoxic spinal cord injury in the rat. Exp Neurol 2001;168:144-154.         [ Links ]

23. Heinrich PC, Castell JV, Andus T - Interleukin-6 and the acute phase response. Biochem J 1990;265:621-636.         [ Links ]

24. Aderka D - The potential biological and clinical significance of the soluble tumor necrosis factor receptors. Cytokine Growth Factor Rev 1996;7:231-240.         [ Links ]

25. Le Roux PJ, Coetzee JF - Tramadol today. Curr Opin Anaesthesiol 2000;13:457-461.         [ Links ]

26. Rowbotham MC, Reisner-Keller LA, Fields HL - Both intravenous lidocaine and morphine reduce the pain of postherpetic neuralgia. Neurology 1991;41:1024-1028.         [ Links ]

27. Sindrup SH, Andersen G, Madsen C et al. - Tramadol relieves pain and allodynia in polyneuropathy: a randomized, double-blind, controlled trial. Pain 1999;83:85-90.         [ Links ]

 

 

Correspondence to:
Dra. Rioko Kimiko Sakata
R. Três de Maio 61/51 Vila Clementino
04044-020 São Paulo, SP
E-mail: riokoks.dcir@epm.br

Submitted em 29 de julho de 2008
Accepted para publicação em 20 de janeiro de 2009

 

 

* Received from Universidade Federal da Bahia (UFBA), Salvado, BA e Universidade Federal de São Paulo (UNIFESP), São Paulo, SP